Therapeutic effects of monoclonal antibodies [19–21] targeting endoglin were already demonstrated, since endoglin expression is highly elevated during the tumor angiogenesis and vascular development, on the proliferating endothelial cells [45,46]. The gene discussed is ENG; the disease is neoplasm.